YKP1447, a novel potential atypical antipsychotic agent

Korean Journal of Physiology and Pharmacology

Volumn 13, Issue 2, 2009, Pages 71-78

  Dong, Seon Min ^a   Kim, Yong Gil ^a   Heo, Joon ^a   Ji, Mi Kyung ^a   Cho, Jeong Woo ^a   Kwak, Byong Sung ^a  

^a SK Holdings Co Ltd   (South Korea)

Author keywords

Atypical antipsychotics; CAR; Catalepsy; Schizophrenia; Serotonin and dopamine receptors; YKP1447

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; CARBAMIC ACID 2 [4 (4 FLUORO BENZOYL) PIPERIDIN 1 YL] 1 PHENYL ETHYL ESTER; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 6 RECEPTOR; UNCLASSIFIED DRUG; YKP 1447;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CATALEPSY; CLIMBING; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HEAD TWITCH; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PSYCHOSIS; RAT;

EID: 67649373261     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2009.13.2.71     Document Type: Article

References (35)

1. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats. Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51: 321-329, 1982.
2. Bartoszyk GD, Amsterdam C van, Bdttdier H, Seyfried CA. EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Fur J Pharmacol 473: 229-230, 2003.
3. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol (Kbh.) 20: 140- 144, 1963.
4. Cook L, Mmris RW, Mattis PA. Neuropharmacological and behavioral effects of chlorpromazine (thorazine hydrochloride). ,J Pharmacol Exp Ther 113: 11-12, 1955.
5. Costentin J, Protais P, Schwartz JC. Rapid and dissociated changes in sensitivities of different dopamine receptors in mouse brain. Nature 257: 405 407, 1975.
6. Dannsmi NA, Martin BR, Pandey U, Glennon RA. Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36: 901-906, 1990.
7. Davidson AB, Weidley E. Differential effects of neuroleptic and other psychotropic agents on acquisition of avoidance in rats. Life Sci 18: 1279-1284, 1976.
8. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 46: 208- 209, 1957.
9. Egashira N, Mishima K. Uchida T, Hasebe N. Nagai H, Mizuki A, Iwasaki K, Ishii H, Nishhnura RJ, Shoyama Y, Fujiwara M, Anandamide inhibits the DOl-induced head-twitch response in mice. Psychopharmacology 171: 382-389, 2004.
10. Gustafsson B, Christensson E. Amperozide, a new putative antipsychotic drug with a limbic mode of action on dopamine mediated behavior. Pharmacol Toxicol 66 Suppl 1: 12-17, 1990.
11. Kroeze WK, Hufeisen SJ, Popadak BA, Renodc SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer 1W, Roth BL Hi-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526, 2003.
12. Janssen PM, Nieniegeers CJE, Smellekens KHL. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Drug Res 15: 56-69, 1965.
13. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 71: 555 568, 2002.
14. Matthysse S. Antipsychotic drug actions: a clue to the pathology of schizophrenia? Fed Proc 32: 200-205, 1973.
15. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuro Psychopharmacol Biol Psychiatr 27: 1159-1172, 2003.
16. Moare NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551, 1992.
17. More 5, Kenyon P. Atypical antipsychotics, elozapine and sulpiride do not antagonize amphetamine-induced stereotyped locomotion. Psychopharmacology 114: 123-130, 1994.
18. Ogren SO, Hall H, Kobler C, Magnusson 0, Lindhan LO, Angeby K, Florvall L Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102: 459-474, 1984.
19. Park WK, Jeong DY, Yun CW, Lee SH, Cho HY, Kim GD, Koh HY, Pae AN, Cho YS, Choi KI,Jung .JY, Jung SH, Kong JY. Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110. Pharm Research 48: 615-622, 2003.
20. Peraitka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, a-sdrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518 1522, 1980.
21. Protais P, Constentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1 - 6, 1976.
22. Protais P, Costentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berlin) 50: 1 6, 1976.
23. Reavill C, Kettle A, Holland V, Riley G, Bladcbuni TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126: 572-574, 1999.
24. Sobreiber R, Broom M, Audinot V, Gobert A, Veiga 5, Millan MJ. (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors : modulation by novel 5-HT2AI2C antagonists, Dl antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112, 1995.
25. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 15: 264-270, 1994.
26. Sibley DR, Monsma Jr FJ, Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol 35: 391-415, 1993.
27. Snyder SH, Banergee SP, Yamamura HI, Greenberg D. Drugs, neurotransmitters and schizophrenia. Science 184: 1243-1245, 1974.
28. Sokokil P, Giros II, Martres MP, Bouthenet ML, Schwartz JC Molecular cloning and characterization of a novel dopamine receptor D3 as a target for neuroleptics. Nature 347: 146- 151, 1990.
29. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmocol Sci 16: 270-275, 1995.
30. Stahl SM. Psychopharmacology of antidepreasanta. 1st ed. Martin Dunitz Ltd, London, p 31-38, 1997.
31. Van Rossum ,JM. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. Arch mt Phormacodyn Ther 160: 492-494, 1966.
32. Wadenherg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biohav Rev 23: 851-862, 1999.
33. Wadenberg ML, Kapur 5, Soliman A, Jones C. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 150: 422-429, 2000.
34. Wilma DL, Meltzer KY. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmocol Exp Ther 282: 699- 706, 1997.
35. Yoon BS, Past EH, Park EH, Kwon JT, Hong SB Dwig SM Kim YH, Heo J, Ji MK Kim YG, Kwak BS, Choi JS, Kim HT. Effects of a new antipsychotic drug (YKP1447) on impaired prspulse inhibition induced by apomorphine and phencyclidine in rats. Korean J Psychopharmacol 19: 38 45, 2008.